Terms: = Sarcomas AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
15 results:
1. ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/akt/MDM2 axis.
Pasello M; Giudice AM; Cristalli C; Manara MC; Mancarella C; Parra A; Serra M; Magagnoli G; Cidre-Aranaz F; Grünewald TGP; Bini C; Lollini PL; Longhi A; Donati DM; Scotlandi K
Cell Oncol (Dordr); 2022 Dec; 45(6):1237-1251. PubMed ID: 36149602
[TBL] [Abstract] [Full Text] [Related]
2. Tetrandrine suppresses the growth of human osteosarcoma cells by regulating multiple signaling pathways.
Wang N; Yang S; Tan T; Huang Y; Chen Y; Dong C; Chen J; Luo X
Bioengineered; 2021 Dec; 12(1):5870-5882. PubMed ID: 34477474
[TBL] [Abstract] [Full Text] [Related]
3. MicroRNA-802 promotes the progression of osteosarcoma through targeting p27 and activating PI3K/akt pathway.
Gao LF; Jia S; Zhang QM; Xia YF; Li CJ; Li YH
Clin Transl Oncol; 2022 Feb; 24(2):266-275. PubMed ID: 34318428
[TBL] [Abstract] [Full Text] [Related]
4. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. clinical outcome and actionable molecular alterations.
Conforti F; Pala L; Pagan E; Rocco EG; Bagnardi V; Montagna E; Peruzzotti G; De Pas T; Fumagalli C; Pileggi S; Pesenti C; Marchini S; Corso G; Marchio' C; Sapino A; Graffeo R; Collet L; Aftimos P; Sotiriou C; Piccart M; Gelber RD; Viale G; Colleoni M; Goldhirsch A
Breast; 2021 Oct; 59():94-101. PubMed ID: 34217971
[TBL] [Abstract] [Full Text] [Related]
5. ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
Reissig TM; Sara L; Ting S; Reis H; Metzenmacher M; Eberhardt WEE; Zaun G; Herold T; Aigner C; Darwiche K; Stuschke M; Schildhaus HU; Schuler M; Wiesweg M
Lung Cancer; 2020 Nov; 149():10-16. PubMed ID: 32947221
[TBL] [Abstract] [Full Text] [Related]
6. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
[TBL] [Abstract] [Full Text] [Related]
7. Effect and Mechanism of
Li X; Liu LF; Liu YZ; Pan YT; Li G; Lu QY; Li ZC
Balkan Med J; 2018 Mar; 35(2):155-162. PubMed ID: 29363485
[TBL] [Abstract] [Full Text] [Related]
8. Integrin-α10 Dependency Identifies rac and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.
Okada T; Lee AY; Qin LX; Agaram N; Mimae T; Shen Y; O'Connor R; López-Lago MA; Craig A; Miller ML; Agius P; Molinelli E; Socci ND; Crago AM; Shima F; Sander C; Singer S
Cancer Discov; 2016 Oct; 6(10):1148-1165. PubMed ID: 27577794
[TBL] [Abstract] [Full Text] [Related]
9. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
[TBL] [Abstract] [Full Text] [Related]
10. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.
Han J; Tian R; Yong B; Luo C; Tan P; Shen J; Peng T
Biochem Biophys Res Commun; 2013 Jun; 435(3):493-500. PubMed ID: 23684620
[TBL] [Abstract] [Full Text] [Related]
11. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Ihle NT; Byers LA; Kim ES; Saintigny P; Lee JJ; Blumenschein GR; Tsao A; Liu S; Larsen JE; Wang J; Diao L; Coombes KR; Chen L; Zhang S; Abdelmelek MF; Tang X; Papadimitrakopoulou V; Minna JD; Lippman SM; Hong WK; Herbst RS; Wistuba II; Heymach JV; Powis G
J Natl Cancer Inst; 2012 Feb; 104(3):228-39. PubMed ID: 22247021
[TBL] [Abstract] [Full Text] [Related]
12. Expression of therapeutic targets in Ewing sarcoma family tumors.
Ahmed AA; Sherman AK; Pawel BR
Hum Pathol; 2012 Jul; 43(7):1077-83. PubMed ID: 22196127
[TBL] [Abstract] [Full Text] [Related]
13. Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome.
Mora J; Rodríguez E; de Torres C; Cardesa T; Ríos J; Hernández T; Cardesa A; de Alava E
Pediatr Blood Cancer; 2012 Apr; 58(4):532-8. PubMed ID: 21994054
[TBL] [Abstract] [Full Text] [Related]
14. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.
Abdeen A; Chou AJ; Healey JH; Khanna C; Osborne TS; Hewitt SM; Kim M; Wang D; Moody K; Gorlick R
Cancer; 2009 Nov; 115(22):5243-50. PubMed ID: 19670450
[TBL] [Abstract] [Full Text] [Related]
15. Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays.
Cheng H; Dodge J; Mehl E; Liu S; Poulin N; van de Rijn M; Nielsen TO
Hum Pathol; 2009 Sep; 40(9):1244-51. PubMed ID: 19368956
[TBL] [Abstract] [Full Text] [Related]